secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0001628280-25-034733
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics shareholders approve reverse stock split authorization at annual meeting
--------------------------------------------------------------------------------

- Elected directors Kevin Fitzgerald and Bart Friedman to three-year terms with >35M votes for each.
- Advisory say-on-pay approved, 35.4M for vs 0.9M against (95% of votes cast).
- Ratified KPMG as independent auditor for FY2025, 50.8M for vs 0.2M against.
- Authorized board to implement reverse stock split at ratio 1:10 to 1:40, at board's discretion (44.2M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828025034733/0001628280-25-034733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828025034733/ovid-20250710.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-034733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer